Action Roche (QX) - RHHBY

Roche Holdings Ltd AG (QX) (RHHBY) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

53,04

( 5,41% )

Prix Achat

52,80

Prix Vente

53,37

Volume échangé

2 082 261

52,25 Fourchette du Jour 53,4967

37,51 Plage de 52 semaines 60,85

Cap du marché

42,2B

Clôture Veille

50,32

Ouverture

52,27

Dernière Transaction

128

53.04

Dernière heure de transaction

Volume financier

US$ 109 808 819

VWAP

52,7354

Volume moyen (3 m)

US$ 1 003 923

Actions en circulation

795 617 637

Rendement du Dividende (LTM)

9,8 (3,11%)

Ratio Cours sur Bénéfices

20,5

Bénéfice par action (BPA)

16,04

Chiffre d'affairess (LTM)

63,36B

Bénéfice net (LTM)

12,88B

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland. Show more

Secteur

Healthcare

Industrie

Pharmaceuticals

Site Web

www.roche.com

Siège social

Basel, Switzerland

Fondé

1896

Roche Holdings Ltd AG (QX) est coté dans le secteur Healthcare de la OTC Markets avec le ticker RHHBY. Le dernier cours de clôture d'Roche (QX) était de US$50,32. Au cours de la dernière année, les actions de Roche (QX) ont été négociées dans une fourchette de prix de US$ 37,51 à US$ 60,85.

Roche (QX) compte actuellement 795 617 637 actions en circulation. La capitalisation boursière d'Roche (QX) est de US$42,20 milliard. Roche (QX) a un ratio cours/bénéfice (ratio PE) de 20.50.

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer...

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

The filing application is based on improvements seen across key efficacy endpoints from the global Phase III SatraGO-1 and SatraGO-2 studies...

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple SclerosisBioMedWire Editorial Coverage: Multiple...

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”...

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

– Filing acceptance based on data from the Phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk...

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50...

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and...

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of...

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	1.76	3.43213728549	51.28	53.4967	50.07	2141267	51.19223366	DR
4	1.93	3.77616904715	51.11	53.4967	48.94	1802109	50.8408696	DR
12	3.71	7.52077843098	49.33	53.54	48.1	2189932	51.08834936	DR
26	1.05	2.01961915753	51.99	60.85	47.05	2462338	52.99979767	DR
52	12.1399	29.6818345187	40.9001	60.85	37.51	2113501	49.44287415	DR
156	14.6	37.9812695109	38.44	60.85	29.2	2099534	40.8498136	DR
260	5.89	12.4920466596	47.15	60.85	27.95	1889784	41.4211331	DR

RHHBY - Frequently Asked Questions (FAQ)

What is the current Roche Holdings Ltd AG (QX) share price?

The current share price of Roche Holdings Ltd AG (QX) is US$ 53,04

How many Roche Holdings Ltd AG (QX) shares are in issue?

Roche Holdings Ltd AG (QX) has 795 617 637 shares in issue

What is the market cap of Roche Holdings Ltd AG (QX)?

The market capitalisation of Roche Holdings Ltd AG (QX) is USD 42,2B

What is the 1 year trading range for Roche Holdings Ltd AG (QX) share price?

Roche Holdings Ltd AG (QX) has traded in the range of US$ 37,51 to US$ 60,85 during the past year

What is the PE ratio of Roche Holdings Ltd AG (QX)?

The price to earnings ratio of Roche Holdings Ltd AG (QX) is 20,5

What is the cash to sales ratio of Roche Holdings Ltd AG (QX)?

The cash to sales ratio of Roche Holdings Ltd AG (QX) is 4,14

What is the registered address of Roche Holdings Ltd AG (QX)?

The registered address for Roche Holdings Ltd AG (QX) is Grenzacherstrasse 124, Basel, Basel-Stadt, 4070

What is the Roche Holdings Ltd AG (QX) website address?

The website address for Roche Holdings Ltd AG (QX) is www.roche.com

Which industry sector does Roche Holdings Ltd AG (QX) operate in?

Roche Holdings Ltd AG (QX) operates in the Pharmaceuticals sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Roche Holdings Ltd AG (QX) (RHHBY)

Roche Holdings Ltd AG (QX) (RHHBY) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Roche Holdings Ltd AG (QX)

RHHBY Dernières nouvelles

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

RHHBY - Frequently Asked Questions (FAQ)

RHHBY Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Roche Holdings Ltd AG (QX) (RHHBY)

Roche Holdings Ltd AG (QX) (RHHBY) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Roche Holdings Ltd AG (QX)

RHHBY Dernières nouvelles

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

RHHBY - Frequently Asked Questions (FAQ)

RHHBY Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités